S&P TSX Capped Composite...

US Dollar vs CAD

Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

ALNY Alnylam Pharmaceuticals Inc

143.95

-3.41 (-2.31%)

Apr 30 2024 - Closed

Delayed by 15 minutes

Confidential Treatment Order (ct Order)

This regulatory filing also includes additional resources:
filename1.pdf

Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Alnylam Pharmaceuticals Charts.

Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Alnylam Pharmaceuticals Charts.

Alnylam Pharmaceuticals, Inc. News

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
Tuesday 30 April 2024 (19 hours ago) • PR Newswire (US)

Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
Thursday 18 April 2024 (2 weeks ago) • Business Wire

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
Sunday 7 April 2024 (3 weeks ago) • Business Wire

Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
Wednesday 20 March 2024 (1 month ago) • Business Wire

Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
Wednesday 13 March 2024 (2 months ago) • Business Wire

Alnylam meldet positive KARDIA-2 Topline-Studienergebnisse, die eine klinisch signifikante Blutdrucksenkung bei Zugabe von Zilebesiran zu Standard-Blutdrucksenkern belegen
Wednesday 6 March 2024 (2 months ago) • Business Wire

Alnylam annonce des résultats positifs de l’étude KARDIA-2 démontrant des réductions cliniquement significatives de la pression artérielle lorsque le zilebesiran est ajouté à des antihypertenseurs standards
Tuesday 5 March 2024 (2 months ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 5 March 2024 (2 months ago) • Edgar (US Regulatory)

Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
Tuesday 5 March 2024 (2 months ago) • Business Wire

More Alnylam Pharmaceuticals, Inc. News Articles

Yuenglings Ice Cream (PK)

Virexit Technologies (PK)

Elite Pharmaceuticals (QB)

Energy One (PK)

BlueFire Equipment (PK)

Canopus Biopharma (PK)

Cann American (CE)

FuelCell Energy

Tonner One World (PK)

Branded Legacy (PK)

AMC Entertainment

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions